Oncology

The ninth annual Trending Now in Cancer Care survey identified current and emerging trends for US cancer programs, such as the ongoing threat of drug costs and popular services progams are planning to add in the next 2 years.

The approval marks the first non-chemotherapy combination regimen for the treatment of patients with chronic lymphocytic leukemia (CLL).

https://www.pharmacytimes.org/on-demand/managed-care-considerations-in-meeting-the-complex-needs-of-patients-with-pancreatic-cancer

As patients with multiple myeloma live longer thanks to advancements in treatments, more attention is being paid to treatment-related toxicities that are becoming more relevant.

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

As the first clinically integrated oncology network, the Quality Cancer Care Alliance (QCCA) brings together the best practices and shares knowledge on value-based care, said Sibel Blau, MD, medical oncologist at Northwest Medical Specialties, PLLC.

Higher tumor mutational burden is associated with improved overall survival in patients with stage IV or metastatic disease being treated with immune checkpoint inhibitors.

Patients with multiple myeloma (MM) who have high-risk cytogenetic abnormalities typically have shorter progression-free survival (PFS) and overall survival (OS) compared with standard-risk patients. In an analysis of 2 studies, patients with high-risk MM had improved outcomes when taking carfilzomib once a week compared with a twice-weekly dose.

AJMC®TV interviews let you catch up on what’s new and important about changes in healthcare, with insights from key decision makers—from the clinician, to the health plan leader, to the regulator. When every minute in your day matters, AJMC®TV interviews keep you informed. Access the video clips at ajmc.com/interviews.

Updates from the annual ASH meeting, December 2018.

This week, the top managed care news included a new investigation into drug prices; FDA Commissioner Scott Gottlieb, MD, provided updates on how the government shutdown is impacting FDA work; research found comorbidities impede clinical trial participation for patients with cancer.

Updates from the annual ASH meeting, December 2018.

Earlier this week, the US Preventive Services Task Force (USPSTF) released a draft guidance recommendations on medications for women at an increased risk for breast cancer.

Updates from the annual ASH meeting, December 2018.

Updates from the annual ASH meeting, December 2018.

Updates from the annual ASH meeting, December 2018.

Updates from annual ASH meeting, December 2018.

Updates from the annual ASH meeting, December 2018.

Updates from the annual ASH meeting, December 2018.

Updates from the Annual ASH meeting, December 2018.

Breast cancer risk estimation models identify women who are at high risk based on a variety of factors, and women who are identified as being at high risk may be able to reduce their chance of breast cancer through preventative measures such as prophylactic surgeries or chemoprevention medications. However, uptake of these preventative treatments varies among racial groups, new research from The Ohio State University finds that racial disparities in healthcare are to blame.

Patients with cancer who have comorbidities are less likely to have clinical trial discussions, be offered a clinical trial, and participate in a clinical trial, according to a new study.

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

This week, the top managed care news included the FDA commissioner discussing boosting drug competition; BMS offering details on its acquisition of Celgene; and cancer mortality rates declining for the 25th consecutive year.

Less than two-thirds of women aged 30 to 65 years were up to date with cervical cancer screenings in 2016. The percentage was even lower for women aged 21 to 29, with just over half up to date on screenings.

For the 25th consecutive year, the cancer mortality rate in the United States has declined, according to The American Cancer Society’s annual report on cancer rates and trends. The overall 27% drop in mortality rate translates into 2.6 million fewer deaths from cancer between the years 1991 and 2016.

New York City is expanding health coverage to 600,000 uninsured residents; a transparency rule requiring hospitals to post prices online is confusing patients; and Eli Lilly has purchased Loxo Oncology in what some are calling a massive bet on cancer genetic.

Bristol-Meyers Squibb (BMS) and Celgene kicked off the 37th Annual JP Morgan Healthcare Conference by discussing their leading drugs, near-term launches, and early pipeline assets.

As a physician, Brian Koffman, MDCM, DCFP, DABFM, MS Ed, medical director, CLL Society, was able to leverage his medical and scientific knowledge during treatment for his chronic lymphocytic leukemia (CLL), and he encourages other patients to educate themselves on their illnesses in order to receive the best care.

Results from the first 2 performance periods of the Oncology Care Model (OCM) highlighted areas where Northwest Medical Specialties was doing well and areas it could improve, said Sibel Blau, MD, medical oncologist at Northwest Medical Specialties, PLLC.